- About the TecnoCampus
- Official Masters eCampus
- eCampus Masters, Postgraduates and Courses
- Timetables and calendars
- Future Undergraduate Student
- Contact information
- TecnoCampus Facilities
- Final Degree Project (TFG)
- HUB4T - Continuing Education Center
- Future Continuing Education Student
- Alumni
- TecnoCampus University Center
- TecnoCampus educational framework
- Teaching staff
- Service for Quality and Teaching Innovation
- Library -CRAI
- University activities
- Communication and press room
- TecnoCampus corporate image
- Events
- Transparency portal
- Equality and Diversity Unit
- Supplier's Office
- Work with us
- TecnoCampus quality
- Innoemprên Sustainable
- Tools for entrepreneurs
- Upcoming events
- Directory of companies in the park
- Business park spaces
- Creatic Awards
- Businesses for sale
- Congress centre
- Health cluster
- Textile cluster
- Circular Economy
- Antena TrenLab Mataró
- ThinkIn 3D
- Mobile World Congress / 4YFN
- Investment day TecnoCampus
What are you looking for?
Minoryx receives a grant of 26,9 million euros under the European IPCEI Med4Cure project for the continued development of leriglitazone in rare and lethal diseases of the central nervous system (CNS)
29 September 2025
Minoryx Therapeutics, a late-stage biotechnology company focused on the development of therapies for rare central nervous system (CNS) disorders, located at TecnoCampus, has obtained a non-dilutive grant of 26,9 million euros for the development of its LERI4CNS project, which will validate leriglitazone for the treatment of potentially lethal rare diseases affecting the CNS. The grant has been awarded within the framework of the pan-European project “Important Project of Common European Interest (IPCEI) Med4Cure”, of which Minoryx Therapeutics is an associate member.
IPCEI Med4Cure is the first Important Project of Common European Interest (IPCEI) in the field of health, approved by the European Commission on 28 May 2024. Its objective is to promote research, innovation and initial industrial deployment of medical products, as well as the development of innovative pharmaceutical production processes. This initiative aims to improve drug discovery, especially for unmet medical needs such as rare diseases, and to foster more innovative and sustainable pharmaceutical processes to strengthen the European Union's healthcare ecosystem.
The programme brings together selected projects led by several companies from six EU Member States —including Spain— and covers the entire pharmaceutical value chain. In Spain, the programme is funded by the CDTI and the Ministry of Science, Innovation and Universities within the framework of the Strategic Project for Economic Recovery and Transformation in the Health Sector (PERTE de Salut). This initiative is part of the Recovery, Transformation and Resilience Plan of Spain, financed by Next Generation EU funds, through the Recovery and Resilience Mechanism (MRR) of the European Union.
In the image, Marc Martinell, CEO of the company.
Institution
Study
Become an entrepreneur
TecnoCampus
Tel. +34 93 169 65 00
info@tecnocampus.cat
Av. Ernest Lluch, 32 | 08302 Mataró
© 2026 TecnoCampus. All rights reserved.
Web project developed by ACTIUM Digital